GlassScriptPhysician profile
Christopher John Karkut
NPI 1922208453
$936.83
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $125 · 2021: $23.44 · 2022: $87.94 · 2023: $135 · 2024: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $247.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $137.45 | 2023-2024 | Zio Xt Patch |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $119.04 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $100.45 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $97.07 | 2019-2024 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $91.69 | 2019-2022 | |
| Amgen INC. | $87.94 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $87.53 | 2019-2022 | |
| United Therapeutics Corporation | $52.07 | 2019 | |
| Pfizer INC. | $47.46 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $43.99 | 2019-2023 | |
| Lexicon Pharmaceuticals, INC. | $19.80 | 2019 | |
| Daiichi Sankyo INC. | $19.32 | 2023 | Injectafer |
| Boston Scientific Corporation | $17.76 | 2020 | |
| Lundbeck LLC | $15.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Karkut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.